Plain-English translation of NCT03290534 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medical device called CivaSheet that delivers radiation directly to lung cancer tumors during surgery. The device is designed to kill cancer cells while protecting your heart and other healthy tissue nearby. Researchers want to see if this new approach works safely and effectively for patients with early-stage lung cancer.
Current radiation treatments for lung cancer can sometimes damage healthy tissues like the heart. This trial exists to test whether this new treatment can deliver cancer-killing radiation more precisely, protecting your heart and other vital structures.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would undergo surgery where doctors place the CivaSheet device directly at the cancer site to deliver radiation treatment. The device stays in your body permanently and works over time to kill cancer cells. Your medical team will monitor you with follow-up visits to check how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
CivaTech Oncology
Enrollment target
~40 participants
Started
March 2019
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.